HELP — Helus Pharma Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1833141 · Ontario, Canada
Last close
$7.20
Market Cap
$526.03M
52W High
$15.15
52W Low
$3.76
ADV30
1,910,236
Next earnings
2027-02-11

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -104,519,000 -103,091,000 263,199,000 171,071,000 18,812,000
Jun 2026 0 — -49,082,000 -47,819,000 259,655,000 166,365,000 17,568,000
Mar 2026 0 — -47,859,000 -46,995,000 251,166,000 157,258,000 19,377,000
Dec 2025 0 — -41,210,000 -42,668,000 290,112,000 195,128,000 16,178,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-140,793,000
Investing CF
$-1,462,000
Financing CF
$190,139,000
CapEx
$-1,462,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.40
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-437,354,000
Inventory
—
Receivables
$5,038,000
ST Investments
—
EBIT TTM
$-167,045,000
Pretax Income TTM
$-171,204,000
Interest Exp TTM
—
Analysts
10

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Mar 2026 0 -142,587,000 -147,998,000 251,166,000 19,377,000 231,789,000 -133,271,000
Mar 2025 0 -103,125,000 -81,607,000 179,897,000 14,900,000 164,997,000 -72,328,000
Mar 2024 0 -78,836,000 -78,080,000 302,023,000 10,096,000 291,927,000 -68,908,000
Mar 2023 0 -51,518,000 -47,490,000 53,897,000 5,663,000 48,234,000 -47,431,000
Mar 2022 — — — — — — —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.83

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $6.00 · spot: $6.89 · call volume: 1,114 · put volume: 1,037
Expected Move to 2027-01-15: ±$3.40 (49.35%) — implied range $3.49 – $10.29 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
EVO Evotec SE $525.98M $1.48 —
ACRS Aclaris Therapeutics, Inc. $536.11M $3.38 —
CBIO CRESCENT BIOPHARMA, INC. $507.20M $13.04 —
AVBP ArriVent BioPharma, Inc. $552.92M $10.69 —
ANL Adlai Nortye Group Ltd. $556.80M $9.48 —

News headlines (Yahoo Finance, 1h cache)

Helus Pharma (HLP) Stock Fair Value Rises After HLP003 Phase 3 Analyst Revisions
2026-11-18 08:12 · Yahoo
HELP Stock Slides As Suicide Attempt Overshadows Strong Late-stage Depression Trial Data
2026-11-16 20:52 · Yahoo
Why Is HELP Stock Rising Today?
2026-11-16 13:50 · Yahoo
Helus Pharma Shares Fall 21% Despite Phase 3 HLP003 Trial Meeting Primary Endpoint
2026-11-16 13:34 · Yahoo
Helus Pharma stock tumbles 21% despite positive trial results
2026-11-16 13:07 · Yahoo
Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder
2026-11-16 12:00 · Yahoo
Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights
2026-11-16 11:00 · Yahoo
Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026
2026-11-15 17:00 · Yahoo
Is Helus Pharma (HELP) Trading At A Premium To Book Value?
2026-11-11 02:16 · Yahoo
Cybin Expects Key Phase III Depression Trial Results This Quarter
2026-11-10 05:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.